HLS Therapeutics Inc. EBITDA for the year ending December 31, 2024: USD 16.39 M

HLS Therapeutics Inc. EBITDA is USD 16.39 M for the year ending December 31, 2024, a 24.93% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • HLS Therapeutics Inc. EBITDA for the year ending December 31, 2023 was USD 13.12 M, a -24.09% change year over year.
  • HLS Therapeutics Inc. EBITDA for the year ending December 31, 2022 was USD 17.28 M, a -31.38% change year over year.
  • HLS Therapeutics Inc. EBITDA for the year ending December 31, 2021 was USD 25.19 M, a 3.15% change year over year.
  • HLS Therapeutics Inc. EBITDA for the year ending December 31, 2020 was USD 24.42 M, a 20.86% change year over year.
Key Data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)